drugset / Trial / NCT06297486
Study of a Gene Therapy Treatment for Hemophilia A
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of SPK-8011 in preventing bleed episodes compared with FVIII prophylaxis in participants with hemophilia A without FVIII inhibitors on routine FVIII prophylaxis.
Timeline
- Start
- 2024-03-13
- Primary completion
- 2027-05
- Completion
- 2035-09-04
Outcome
Outcome not reported
Stopped (Business): “Strategic Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DIRLOCTOCOGENE SAMOPARVOVEC | Gene therapy (AAV / viral vector) | — | Intravenous |